NOVA WELLNESS GROUP |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.52 MYR | -0.95% |
|
0.00% | -16.13% |
| Feb. 20 | Nova Wellness Group Berhad Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023 | CI |
| 2023 | Nova Wellness' Profit, Revenue Drop in Fiscal Q1 | MT |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- With a P/E ratio at 11.39 for the current year and 10.06 for next year, earnings multiples are highly attractive compared with competitors.
- The company is one of the best yield companies with high dividend expectations.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The opinion of analysts covering the stock has improved over the past four months.
Weaknesses
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Food Processing
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -16.13% | 34.76M | C- | ||
| +8.20% | 7.78B | D+ | ||
| +1.64% | 7.38B | C- | ||
| +10.20% | 6.52B | - | ||
| -8.10% | 3.67B | D | ||
| -12.93% | 3.44B | B- | ||
| -14.57% | 1.17B | - | - | |
| +8.34% | 934M | - | ||
| -40.89% | 879M | B+ | ||
| -17.65% | 836M | C+ |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
- Stock Market
- Equities
- NOVA Stock
- Ratings Nova Wellness Group
